CDEK by Data4ThePeople
Sign in Sign up
← All organizations

Sarepta Therapeutics

For profitContributed to NMEWebsite ↗

Also known as: AVI BioPharma | AVI BioPharma, Director, Clinical Operations | Jerry R. Mendell | Sarepta Therapeutics | Sarepta Therapeutics Inc. | Sarepta Therapeutics, Inc. | SAREPTA THERAPS INC

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Aug 1, 2003

First marketed drug

Feb 13, 2015

First NDA

Sep 19, 2016

Last known activity

Aug 29, 2025

Timeline

1980s

  1. Jan 1, 1980

    Sarepta Therapeutics— Founded

2000s

  1. Mar 20, 2008

    Ercole Biotech— Acquired

2010s

  1. Jan 1, 2014

    Eisai— Acquired

  2. Feb 27, 2019

    Myonexus Therapeutics— Acquired

  3. Dec 12, 2019

    golodirsen— Marketing Organization

  4. Dec 20, 2019

    lemborexant— NDA Secondary Org

2020s

  1. Jan 6, 2023

    LECANEMAB— NDA Organization

Drugs by trial phase (239 distinct, 780 trials)

Other trials (0 own, 2 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (9)

Subsidiaries (3 direct, 11 total across the full acquisition tree)

Recent trials (50)

Details

Founded
Corvallis, OR, US Jan 1, 1980
First NDA
Sep 19, 2016
Last known activity
Aug 29, 2025

Designations held

  • Orphan drug
  • Fast track
  • Priority review
  • Breakthrough therapy
  • Accelerated approval

Notes

--- Notes from AVI BioPharma: Acquired by Sarepta in 1 July 2012 ---